The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community
Open accessAbstract
Objectives We sought to examine the relation of galectin-3 (Gal-3), a marker of cardiac fibrosis, with incident heart failure (HF) in the community. Background Gal-3 is an emerging prognostic biomarker in HF, and experimental studies suggest that Gal-3 is an important mediator of cardiac fibrosis. Whether elevated Gal-3 concentrations precede the development of HF is unknown. Methods Gal-3 concentrations were measured in 3,353 participants in the Framingham Offspring Cohort (mean age 59 years, 53% women). The relation of Gal-3 to incident HF was assessed using proportional hazards regression. Results Gal-3 was associated with increased left ventricular mass in age- and sex-adjusted analyses (P=0.001); this association was attenuated in multivariable analyses (P=0.06). A total of 166 participants developed incident HF and 468 died during a mean follow-up of 8.1 years. Gal-3 was associated with risk of incident HF (HR 1.28 per 1 standard deviation increase in log-Gal-3, 95% CI 1.14–1.43, P<0.0001), and remained significant after adjustment for clinical variables and B-type natriuretic peptide (HR 1.23, 95% CI 1.04–1.47, P=0.02). Gal-3 was also associated with risk of all-cause mortality (multivariable-adjusted HR 1.15, 95% CI 1.04–1.28, P=0.01). The addition of Gal-3 to clinical factors resulted in negligible changes to the c-statistic and minor improvements in the net reclassification index. Conclusions Higher concentration of Gal-3, a marker of cardiac fibrosis, is associated with increased risk of incident HF and mortality. Future studies evaluating the role of Gal-3 in cardiac remodeling may provide further insights into the role of Gal-3 in the pathophysiology of HF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Sahn, D. J., DeMaria, A., Kisslo, J., & Weyman, A. (1978) · Circulation · doi:10.1161/01.cir.58.6.1072 · Cited by 7,430
Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31823ac046 · Cited by 7,333
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493 · cited 1×
“We estimated the integrated discrimiation improvement (IDI) and the category-free net reclasification improvement (NRI) metric for the addition of al-3 in fully adjusted models (25,26).”
MethodSelf-citationEchocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings
Devereux, R. B., Alonso, D. R., Lutas, E. M., Gottlieb, G. J., Campo, E., Sachs, I., & Reichek, N. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90771-x · Cited by 6,229
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
Tarver, T. (2014) · Journal of Consumer Health On the Internet · doi:10.1080/15398285.2014.902284 · Cited by 5,605
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,154
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,418
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2017.04.014 · Cited by 770
Matrix Metalloproteinase-9: Many Shades of Function in Cardiovascular Disease
Yabluchanskiy, A., Ma, Y., Iyer, R. P., Hall, M. E., & Lindsey, M. L. (2013) · Physiology · doi:10.1152/physiol.00029.2013 · Cited by 635
Chow, S. L., Maisel, A. S., Anand, I., Bozkurt, B., de Boer, R. A., Felker, G. M., Fonarow, G. C., Greenberg, B., Januzzi, J. L., Kiernan, M. S., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000490 · Cited by 601
Redefining the identity of cardiac fibroblasts
Tallquist, M. D., & Molkentin, J. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.57 · Cited by 581
Targeting metabolic dysregulation for fibrosis therapy
Zhao, X., Kwan, J. Y. Y., Yip, K., Liu, P. P., & Liu, F.-F. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0040-5 · Cited by 513
Tsao, C. W., & Vasan, R. S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv337 · Cited by 457
Self-citationYu, L., Ruifrok, W. P. T., Meissner, M., Bos, E. M., van Goor, H., Sanjabi, B., van der Harst, P., Pitt, B., Goldstein, I. J., Koerts, J. A., et al. (2013) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.971168 · Cited by 435
Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z
Sciacchitano, S., Lavra, L., Morgante, A., Ulivieri, A., Magi, F., De Francesco, G., Bellotti, C., Salehi, L., & Ricci, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020379 · Cited by 377
Cardiorenal Syndrome Revisited
Zannad, F., & Rossignol, P. (2018) · Circulation · doi:10.1161/circulationaha.117.028814 · Cited by 335
ter Maaten, J. M., Damman, K., Verhaar, M. C., Paulus, W. J., Duncker, D. J., Cheng, C., van Heerebeek, L., Hillege, H. L., Lam, C. S. P., Navis, G., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.497 · Cited by 320
Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update
Suthahar, N., Meijers, W. C., Silljé, H. H. W., Ho, J. E., Liu, F.-T., & de Boer, R. A. (2018) · Theranostics · doi:10.7150/thno.22196 · Cited by 309
Self-citationAging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling
Horn, M. A., & Trafford, A. W. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.11.005 · Cited by 275
Functions of Galectin-3 and Its Role in Fibrotic Diseases
Li, L.-C., Li, J., & Gao, J. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.218370 · Cited by 261
de Boer, R. A., Nayor, M., deFilippi, C. R., Enserro, D., Bhambhani, V., Kizer, J. R., Blaha, M. J., Brouwers, F. P., Cushman, M., Lima, J. A. C., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2017.4987 · Cited by 260
Self-citationBayes-Genis, A., de Antonio, M., Vila, J., Peñafiel, J., Galán, A., Barallat, J., Zamora, E., Urrutia, A., & Lupón, J. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.087 · Cited by 259
Galectin-3 increase in endurance athletes
Hättasch, R., Spethmann, S., de Boer, R. A., Ruifrok, W. P., Schattke, S., Wagner, M., Schroeckh, S., Durmus, T., Schimke, I., Sanad, W., et al. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487313492069 · Cited by 46
“Recently, galectin-3 has emerged as a new biomarker for heart failure and for all-cause mortality in the general population.(7,8) Moreover, plasma galectin-3 levels in humans are an independent predictor for outcome in acute and chronic heart failure.”
BackgroundDepression in type 1 diabetes was associated with high levels of circulating galectin-3
Melin, E. O., Dereke, J., Thunander, M., & Hillman, M. (2018) · Endocrine Connections · doi:10.1530/ec-18-0108 · Cited by 31
Metadata
- Authors
- Ho, J. E., Liu, C., Lyass, A., Courchesne, P., Pencina, M. J., Vasan, R. S., Larson, M. G., & Levy, D.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 60
- Issue
- 14
- Pages
- 1249-1256
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2048178709
- Cited by
- 589
- References
- 40
- FWCI
- 26.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.